Is anemia of cancer different from chemotherapy-induced anemia?

Journal of Clinical Oncology

Volumn 26, Issue 7, 2008, Pages 1022-1024

  Steensma, David P ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYTOTOXIC AGENT; HORMONE ANTAGONIST; IMATINIB; IMMUNOMODULATING AGENT; MONOCLONAL ANTIBODY; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PHOSPHOTRANSFERASE INHIBITOR; RAPAMYCIN; ANTIANEMIC AGENT; DRUG DERIVATIVE; ERYTHROPOIETIN;

ANEMIA; CANCER PATIENT; EDITORIAL; ERYTHROCYTE TRANSFUSION; GASTROINTESTINAL STROMAL TUMOR; HEAD AND NECK CANCER; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY CARCINOMA; MONOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE; CHEMICALLY INDUCED DISORDER; NEOPLASM; NOTE;

ANEMIA; ANTINEOPLASTIC AGENTS; ERYTHROPOIETIN; HEMATINICS; HUMANS; NEOPLASMS;

EID: 41949129089     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.3874     Document Type: Editorial

References (29)

1. Spivak JL: The anaemia of cancer: Death by a thousand cuts. Nat Rev Cancer 5:543-555, 2005
2. Smith RE Jr, Aapro M, Ludwig H, et al: Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 26:1040-1050, 2008
3. Glaspy J, Smith R, Aapro M, et al: Abstract LB-3. Results from a phase III, randomized, double-blind, placebo-controlled study of darbepoetin alfa (DA) for the treatment of anemia in patients not receiving chemotherapy or radiotherapy. Presented at the 98th annual meeting of the Am Assoc Cancer Res, Los Angeles, CA, April 14-18, 2007
4. Pollack A: Amgen seeks to reverse its bad news. The New York Times, 2007
5. Steinbrook R: Medicare and erythropoietin. N Engl J Med 356:4-6, 2007
6. Timiraos N: Amgen spends big protesting curbs on anemia drugs. The Wall Street Journal, November 13, 2007, pp B1
7. Henke M, Laszig R, Rube C, et al: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, doubleblind, placebo-controlled trial.[see comment]. Lancet 362:1255-1260, 2003
8. Leyland-Jones B, Semiglazov V, Pawlicki M, et al: Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol 23:5960-5972, 2005
9. Rouger P: Blood transfusion in Europe: The white book 2005. Paris, France, Elsevier, 2005, pp 250
10. Rowland C: Clinical trials seen shifting overseas. Int J Health Serv 34:555-556, 2004
11. Kolata G: Companies facing ethical issue as drugs are tested overseas. The New York Times, March 5, 2004, pp A1, A15
12. Berenson A, Pollack A: Doctors reap millions for anemia drugs. The New York Times, May 9, 2007, pp A1, A15
13. Goldberg P: Study finds more deaths on Aranesp arm in cancer anemia study, no benefit seen. The Cancer Letter 33:1, 2007
14. Crawford J: Erythropoietin: High profile, high scrutiny. J Clin Oncol 25:1021-1023, 2007
15. Ludwig H, Fritz E, Kotzmann H, et al: Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 322:1693-1699, 1990
16. Oster W, Herrmann F, Gamm H, et al: Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration. J Clin Oncol 8:956-962, 1990
17. Luksenberg H, Weir A, Wager R: FDA briefing document: May 4, 2004 Oncologic Drugs Advisory Committee. Safety concerns associated with Aranesp (darbepoetin alfa, Amgen, Inc.) and Procrit (epoetin alfa, Ortho Biotech, L.P.), for the treatment of anemia associated with cancer chemotherapy. Http://www.fda.gov/ohrms/dockets/AC/04/briefing/4037B2_04_FDA-Aranesp-Procrit. htm. Accessed October 31, 2007
18. Crawford J: Recombinant human erythropoietin in cancer-related anemia: Review of clinical evidence. Oncology (Williston Park) 16:41-53, 2002
19. Henry DH, Abels RI: Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: Results of double-blind and open-label follow-up studies. Semin Oncol 21:21-28, 1994
20. Smith RE Jr, Tchekmedyian NS, Chan D, et al: A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer. Br J Cancer 88:1851-1858, 2003
21. Anonymous: Amgen drug comes off drug list for 1 use. Associated Press wire service release dated February 23, 2007. Accessed at: Http://www.forbes. com/feeds/ap/2007/02/23/ap3457659.html on March 12, 2007
22. Glaspy J, Vadhan-Raj S, Patel R, et al: Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: The 20030125 Study Group Trial. J Clin Oncol 24:2290-2297, 2006
23. Bohlius J, Wilson J, Seidenfeld J, et al: Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 3:CD003407, 2006
24. Vamvakas EC, Blajchman MA: Transfusion-related immunomodulation (TRIM): An update. Blood Rev 21:327-348, 2007
25. Duffaud F, Lecesne A, Ray-Coquard I, et al: Erythropoietin for anemia treatment of patients with GIST receiving imatinib. J Clin Oncol 22: , 2004 (suppl, abstr)
26. Motzer RJ, Rini BI, Bukowski RM, et al: Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295:2516-2524, 2006
27. Atkins MB, Hidalgo M, Stadler WM, et al: Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22:909-918, 2004
28. Rizzo JD, Somerfield MR, Hagerty KL, et al: American Society of Hematology/American Society of Clinical Oncology 2007 clinical practice guideline update on the use of epoetin and darbepoetin. Blood Epub October 23, 2007
29. Steensma DP: New ASH/ASCO guidelines on the use of erythropoiesis- stimulating agents: A chorale amid cacophony. J Support Oncol 5:471-472, 2007